Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2019

In 2019, Anika Therapeutics Inc.'s disclosed short interest ran from 16.87% of shares outstanding on 15 Jan 2019 to 16.10% on 31 Dec 2019, a change of -0.77 percentage points. The year's high was 23.86% on 31 Jul 2019 and its low 13.84% on 15 Nov 2019, averaging 18.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.48 days on 15 Jul 2019. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2019

2019 in figures

Start of year
16.87% (15 Jan 2019)
End of year
16.10% (31 Dec 2019)
Change
-0.77 pp
High
23.86% (31 Jul 2019)
Low
13.84% (15 Nov 2019)
Average
18.11%
Highest days to cover
26.48 (15 Jul 2019)
SEC filings marked
8

Every report in 2019

Anika Therapeutics Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201916.87%14.43
31 Jan 201916.55%24.54
15 Feb 201915.92%23.32
28 Feb 201915.92%11.55results (8-K), 10-K filed
15 Mar 201916.24%7.29
29 Mar 201918.05%19.12
15 Apr 201918.10%19.13
30 Apr 201918.49%16.63
15 May 201922.14%11.14results (8-K), 10-Q filed
31 May 201922.70%20.44
14 Jun 201922.22%25.60
28 Jun 201922.70%19.19
15 Jul 201923.11%26.48
31 Jul 201923.86%9.51results (8-K), 10-Q filed
15 Aug 201919.55%12.98
30 Aug 201918.52%16.19
13 Sep 201918.05%18.22
30 Sep 201916.35%11.64
15 Oct 201914.68%13.45
31 Oct 201915.00%7.61results (8-K), 10-Q filed
15 Nov 201913.84%13.13
29 Nov 201914.54%20.11
13 Dec 201915.05%16.57
31 Dec 201916.10%13.73

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.